A
KROS icon

AlphaQuest’s Keros Therapeutics KROS Stock Holding History

AlphaQuest’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,090
Closed -$653K – 1081
2025
Q4 		$653K Buy
32,090
+16,841
+110% +$295K 0.04% 642
2025
Q3 		$241K Sell
15,249
-10,709
-41% -$158K 0.02% 1297
2025
Q2 		$347K Buy
25,958
+12,724
+96% +$172K 0.03% 803
2025
Q1 		$135K Buy
13,234
+9,638
+268% +$112K 0.01% 1167
2024
Q4 		$56.9K Buy
3,596
+2,964
+469% +$154K 0.01% 1261
2024
Q3 		$36.7K Sell
632
-4,177
-87% -$206K ﹤0.01% 1459
2024
Q2 		$220K Buy
4,809
+4,789
+23,945% +$257K 0.03% 715
2024
Q1 		$1.32K Sell
20
-366
-95% -$21.7K ﹤0.01% 1217
2023
Q4 		$15.3K Buy
+386
New +$12.1K ﹤0.01% 978

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

AlphaQuest's KROS Position: Q1 2026 in Review

AlphaQuest sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 32,090 shares — an estimated $653K sold.

AlphaQuest first reported a position in KROS in Q4 2023 and held it in 9 quarters. The position peaked at $653K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • AlphaQuest reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 32,090 Keros Therapeutics shares in Q1 2026, an estimated $653K.
  • AlphaQuest first reported a position in Keros Therapeutics in Q4 2023 and held it in 9 quarters.
  • AlphaQuest's Keros Therapeutics position peaked at $653K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.